142 related articles for article (PubMed ID: 29678478)
1. Immunohistochemical CD271 expression correlates with melanoma progress in a case-control study.
Nielsen PS; Riber-Hansen R; Steiniche T
Pathology; 2018 Jun; 50(4):402-410. PubMed ID: 29678478
[TBL] [Abstract][Full Text] [Related]
2. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.
Boiko AD; Razorenova OV; van de Rijn M; Swetter SM; Johnson DL; Ly DP; Butler PD; Yang GP; Joshua B; Kaplan MJ; Longaker MT; Weissman IL
Nature; 2010 Jul; 466(7302):133-7. PubMed ID: 20596026
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of melanoma stem cell marker CD271 in metastatic melanoma to the brain.
Guo R; Fierro-Fine A; Goddard L; Russell M; Chen J; Liu CZ; Fung KM; Hassell LA
Int J Clin Exp Pathol; 2014; 7(12):8947-51. PubMed ID: 25674270
[TBL] [Abstract][Full Text] [Related]
4. Automated quantification of MART1-verified Ki-67 indices: useful diagnostic aid in melanocytic lesions.
Nielsen PS; Spaun E; Riber-Hansen R; Steiniche T
Hum Pathol; 2014 Jun; 45(6):1153-61. PubMed ID: 24704158
[TBL] [Abstract][Full Text] [Related]
5. CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.
Boyle SE; Fedele CG; Corbin V; Wybacz E; Szeto P; Lewin J; Young RJ; Wong A; Fuller R; Spillane J; Speakman D; Donahoe S; Pohl M; Gyorki D; Henderson MA; Johnstone RW; Papenfuss AT; Shackleton M
Cancer Res; 2016 Jul; 76(13):3965-77. PubMed ID: 27325642
[TBL] [Abstract][Full Text] [Related]
6. CD271 is expressed in melanomas with more aggressive behaviour, with correlation of characteristic morphology by in vivo reflectance confocal microscopy.
Beretti F; Manni P; Longo C; Argenziano G; Farnetani F; Cesinaro AM; Witkowski AM; De Pol A; Pellacani G
Br J Dermatol; 2015 Mar; 172(3):662-8. PubMed ID: 25066225
[TBL] [Abstract][Full Text] [Related]
7. Tumor stem cells (CD271, c-kit, SOX10) in Melanomas: prognostic and outcome implications.
Mohamed A; Gonzalez RS; Lawson D; Wang J; Cohen C
Appl Immunohistochem Mol Morphol; 2014; 22(2):142-5. PubMed ID: 23958542
[TBL] [Abstract][Full Text] [Related]
8. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
9. Automated quantification of Ki67/MART1 stains may prevent false-negative melanoma diagnoses.
Wandler A; Spaun E; Steiniche T; Nielsen PS
J Cutan Pathol; 2016 Nov; 43(11):956-962. PubMed ID: 27461337
[TBL] [Abstract][Full Text] [Related]
10. CD166high Uveal Melanoma Cells Represent a Subpopulation With Enhanced Migratory Capacity.
Djirackor L; Kalirai H; Coupland SE; Petrovski G
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2696-2704. PubMed ID: 31242292
[TBL] [Abstract][Full Text] [Related]
11. Automated quantification of MART1-verified Ki67 indices by digital image analysis in melanocytic lesions.
Nielsen PS; Riber-Hansen R; Raundahl J; Steiniche T
Arch Pathol Lab Med; 2012 Jun; 136(6):627-34. PubMed ID: 22646269
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity.
Li S; Yue D; Chen X; Wang L; Li J; Ping Y; Gao Q; Wang D; Zhang T; Li F; Yang L; Huang L; Zhang Y
Oncol Rep; 2015 Jan; 33(1):425-32. PubMed ID: 25351876
[TBL] [Abstract][Full Text] [Related]
13. Expression of SOX10, ABCB5 and CD271 in melanocytic lesions and correlation with survival data of patients with melanoma.
Gambichler T; Petig AL; Stockfleth E; Stücker M
Clin Exp Dermatol; 2016 Oct; 41(7):709-16. PubMed ID: 27663144
[TBL] [Abstract][Full Text] [Related]
14. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract][Full Text] [Related]
15. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth.
Civenni G; Walter A; Kobert N; Mihic-Probst D; Zipser M; Belloni B; Seifert B; Moch H; Dummer R; van den Broek M; Sommer L
Cancer Res; 2011 Apr; 71(8):3098-109. PubMed ID: 21393506
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cancer stem cells from different grades of human colorectal cancer.
Manhas J; Bhattacharya A; Agrawal SK; Gupta B; Das P; Deo SV; Pal S; Sen S
Tumour Biol; 2016 Oct; 37(10):14069-14081. PubMed ID: 27507615
[TBL] [Abstract][Full Text] [Related]
17. CD271 is an imperfect marker for melanoma initiating cells.
Cheli Y; Bonnazi VF; Jacquel A; Allegra M; De Donatis GM; Bahadoran P; Bertolotto C; Ballotti R
Oncotarget; 2014 Jul; 5(14):5272-83. PubMed ID: 25105565
[TBL] [Abstract][Full Text] [Related]
18. The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells.
Redmer T; Welte Y; Behrens D; Fichtner I; Przybilla D; Wruck W; Yaspo ML; Lehrach H; Schäfer R; Regenbrecht CR
PLoS One; 2014; 9(5):e92596. PubMed ID: 24799129
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions.
Nielsen PS; Riber-Hansen R; Steiniche T
Am J Dermatopathol; 2011 Jun; 33(4):361-70. PubMed ID: 21610457
[TBL] [Abstract][Full Text] [Related]
20. Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Schmidt H; Steiniche T
Diagn Pathol; 2016 Apr; 11():35. PubMed ID: 27062658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]